News about "RAS G12D"

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib

Revolution Medicines presented phase 1/2 clinical data showing the potential of zoldonrasib combination regimens in patients with RAS G12D metastatic pancreatic cancer at ESMO Gastrointestinal Cancers Congress 2026.

RAS G12D | 04/07/2026 | By News Bureau


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members